REFERENCES

• LantosPL.The neuropathology of schizophrenia. Progress and interpretation.J Neurol Neurosurg Psychiatry.2001 70421
   Google Scholar
• BaronM.Genetics of schizophrenia and the new millennium: progress and pitfalls.Am J Hum Genet.20016829931211170887
   PubMed Web of Science ®Google Scholar
• BuckleyPF.BuchananRW.TammingaCA.ShultzSC.Schizophrenia research: a progress report, summarizing proceedings of the 1999 International Congress on Schizophrenia Research.Schizophr Bull.20002641141910885640
   PubMed Web of Science ®Google Scholar
• BeratisS.GabrielJ.HoidasS.Age at onset in subtypes of schizophrenic disorders.Schizophr Bull.1994202872968085133
   PubMed Web of Science ®Google Scholar
• HafnerH.Riecher-RosslerA.MaurerK.FatkenheuerB.LoftierW.First onset and early symptomatology of schizophrenia: a chapter of epidemiological and neurobiological research into age and sex differences.Eur Arch Psychiatry Clin Neurosci.19922421091 181486099
   PubMed Web of Science ®Google Scholar
• LorangerAW.Sex difference in age at onset of schizophrenia.Arch Gen Psychiatry.1984411571616696597
   PubMed Web of Science ®Google Scholar
• WerryJS.Child and adolescent (early onset) schizophrenia: a review in light of DSM-III-R.J Autism Dev Disord.1992226016241483979
   PubMed Web of Science ®Google Scholar
• WerryJS.McClellanJM.ChardL.Childhood and adolescent schizophrenia, bipolar, and schizoaffective disorders: a clinical and outcome study.J Am Acad Child Adolesc Psychiatry.1991304574652055884
   PubMed Web of Science ®Google Scholar
• GreenWH.Padron-GayolM.HardestyAS.BassiriM.Schizophrenia with childhood onset: a phenomenological study of 38 cases.J Am Acad Child Adolesc Psychiatry.1992319689761400132
   PubMed Web of Science ®Google Scholar
• RussellAT.BottL.SammonsC.The phenomenology of schizophrenia occurring in childhood.J Am Acad Child Adolesc Psychiatry.1989283994072738007
   PubMed Web of Science ®Google Scholar
• WatkinsJM.AsarnowRF.TanguayPE.Symptom development in childhood-onset schizophrenia.J Child Psychol Psychiatry.1988298658783235494
   PubMed Web of Science ®Google Scholar
• AsarnowJR.Ben-MeirS.Children with schizophrenia spectrum and depressive disorders: a comparative study of premorbid adjustment, onset pattern and severity of impairment.J Child Psychol Psychiatry.1988294774883215919
   PubMed Web of Science ®Google Scholar
• FindlingRL.GrcevichSJ.LopezI.SchulzSC.Antipsychotic medications in children and adolescents.J Clin Psychiatry.199657(suppl 9) 19238823346
   PubMed Web of Science ®Google Scholar
• PoolD.BloomW.MielkeDH.RonigerJj.GallantDM.A controlled evaluation of loxitane in 75 adolescent schizophrenic patients.Curr Ther Res Clin Exp.19761999104812671
   PubMed Web of Science ®Google Scholar
• RealmutoGM.EricksonWD.YellinAM.HopwoodJH.GreenbergLM.Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents.Am J Psychiatry.19841414404426367494
   PubMed Web of Science ®Google Scholar
• SpencerEK.KafantarisV.Padron-GayolMV.etal.Haloperidol in schizophrenic children: early findings from a study in progress.Psychopharmacol Bull.1992281831861513922
   PubMed Web of Science ®Google Scholar
• FrazierJA.GordonCT.McKennaK.LenaneMC.JihD.RapopotJL.An open trial of clozapine in 1 1 adolescents with childhood-onset schizophrenia. J AmAcad Child Adolesc Psychiatry.199433658663
   PubMed Web of Science ®Google Scholar
• RemschmidtH.SchulzE.MartinM.An open trial of clozapine in 36 adolescents with schizophrenia.J Child Adolesc Psychopharmacol.1 99443141
   Web of Science ®Google Scholar
• BirmaherB.BakerR.KapurS.QuintanaH.GanguliR.Clozapine for the treatment of adolescents with schizophrenia.J Am Acad Child Adolesc Psychiatry.1992311601641537770
   PubMed Web of Science ®Google Scholar
• KowatchRA.SuppesT.GilfillanSK.et al.Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series.J Child Adolesc Psychopharmacol.19955241253
   Web of Science ®Google Scholar
• MozesT.TorenP.ChernauzanN.et al.Clozapine treatment in very early onset schizophrenia.J Am Acad Child Adolesc Psychiatry.19943365708138523
   PubMed Web of Science ®Google Scholar
• KumraS.FrazierJA.JacobsenLK.et al.Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison.Arch Gen Psychiatry.199653109010978956674
   PubMed Web of Science ®Google Scholar
• McDougleCJ.ScahillL.McCrackenJT.et al.Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.Child Adolesc Psychiatr Clin N Ami.20009201224
   PubMed Web of Science ®Google Scholar
• PerryR.PatakiC.Munoz-SilvaDM.ArmenterosJ.SilvaRR.Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.J Child Adolesc Psychopharmacol.199771671799466234
   PubMed Web of Science ®Google Scholar
• McDougleCJ.HolmesJP.BransonMR.et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J AmAcad Child Adolesc Psychiatry.199736685693
   PubMed Web of Science ®Google Scholar
• FismanS.SteeleM.PipherB.Risperidone in PDD .J Am Acad Child Adolesc Psychiatry.19983715169444894
   PubMed Web of Science ®Google Scholar
• DurstR.Rubin-JabotinskyK.RaskinS.KatzG.ZislinJ.Risperidone in treating behavioral disturbances of Prader-Willi syndromeActa Psychiatr Scand.200010246146511142437
   PubMed Web of Science ®Google Scholar
• SchreierHA.Risperidone for young children with mood disorders and aggressive behavior.J Child Adolesc Psychopharmacol.1998849599639079
   PubMed Web of Science ®Google Scholar
• FrazierJA.MeyerMC.BiedermanJ.et al.Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.J Am Acad Child Adolesc Psychiatry.19993896096510434487
   PubMed Web of Science ®Google Scholar
• KewleyGD.Risperidone in comorbid ADHD and ODD/CD.J Am Acad Child Adolesc Psychiatry.1999381327132810560215
   PubMed Web of Science ®Google Scholar
• HannaGL.FluentTE.FischerDJ.Separation anxiety in children and adolescents treated with risperidone.J Child Adolesc Psychopharmacol.1999927728310630458
   PubMed Web of Science ®Google Scholar
• BuitelaarJK.Open-label treatment with risperidone of 26 psychiatrically hospitalized children and adolescents with mixed diagnoses and aggressive behavior. JChild Adolesc Psychopharmacol.2000101926
   PubMed Web of Science ®Google Scholar
• FindlingRL.McNamaraNK.Branick'yLA.SchluchterMD.LemonE.BlumerJL.A double-blind pilot study of risperidone in the treatment of conduct disorder.J Am Acad Child Adolesc Psychiatry.20003950951610761354
   PubMed Web of Science ®Google Scholar
• FitzgeraldKD.StewartCM.TawileV.RosenbergDR.Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.J Child Adolesc Psychopharmacol.1999915123
   Web of Science ®Google Scholar
• ArmenterosJL.WhitakerAH.WeliksonM.StedgeDJ.GormanJ.Risperidone in adolescents with schizophrenia: an open pilot study.J Am Acad Child Adolesc Psychiatry.1997366947009136505
   PubMed Web of Science ®Google Scholar
• MarderSR.MeibackRC.Risperidone in the treatment of schizophrenia.Am J Psychiatry.19941518258357514366
   PubMed Web of Science ®Google Scholar
• LoveRC.ConleyRR.KellyDL.BartkoJJ.A dose-outcome analysis of risperidone.J Clin Psychiatry.19996077177510584767
   PubMed Web of Science ®Google Scholar
• KumraS.HerionD.jacobsenLK.BrigugliaC.GrotheD.Case study: risperidone-induced hepatotoxicity in pediatric patients.J Am Acad Child Adolesc Psychiatry.1997367017059136506
   PubMed Web of Science ®Google Scholar
• KellyDL.ConleyRR.LoveRC.HornDS.UshchakCM.Weight gain in adolescents treated with risperidone and conventional antipsychotics over 6 months.J Child Adolesc Psychopharmacol.199881511599853689
   PubMed Web of Science ®Google Scholar
• MartinA.LandauJ.LeebensP.et al.Risperidone-associated weight gain in children and adolescents: a retrospective chart review.J Child Adolesc Psychopharmacol.20001025926811191686
   PubMed Web of Science ®Google Scholar
• LavalayeJ.LinszenDH.BooijJ.RenemanL.GersonsBP.van RoyenEA.Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.Psychiatry Res.199992334410688158
   PubMed Web of Science ®Google Scholar
• ZuddasA.Di MartinoA.MugliaP.CianchettiC.Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.J Child Adolesc Psychopharmacol.200010799010933118
   PubMed Web of Science ®Google Scholar
• BeasleyCM.TollefsonG.TranP.et al.Olanzapine versus placebo and haloperidol; acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology1996141111238822534
   PubMed Web of Science ®Google Scholar
• KumraS.jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open label study of olanzapine in adolescents.J Am Acad Adolesc Psychiatry.199837377385
   PubMed Web of Science ®Google Scholar
• PotenzaMM.HolmesJP.KanesSJ.McDougleCJ.Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: an open-label pilot study.J Clin Psychopharmacol.19991937449934941
   PubMed Web of Science ®Google Scholar
• WudarskyM.NicolsonR.HambergerSD.et al.Elevated prolactin in pediatric patients on typical and atypical antipsychotics.J Child Adolesc Psychopharmacol.1999923924510630453
   PubMed Web of Science ®Google Scholar
• McConvilleBJ.ArvanitisLA.ThyrurnPT.et al.Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.J Clin Psychiatry.20006125226010830145
   PubMed Web of Science ®Google Scholar
• ThorpeL.The treatment of psychotic disorders in late life.Can J Psychiatry.199742(suppl 1)19S27S9220126
   PubMed Web of Science ®Google Scholar
• The epidemiology of mental disorders: results from the Epidemiologic Catchment Area Study (ECA).Psychopharmaocol Bull.198218222225
   PubMedGoogle Scholar
• WraggRE.JesteDV.Overview of depression and psychosis in Alzheimer's disease.Am J Psychiatry.19891465775872653053
   PubMed Web of Science ®Google Scholar
• JesteDV.EasthamJH.LacroJP.GierzM.FieldMG.HarrisMJ.Management of late-life psychosis.J Clin Psychiatry.19965739458626369
   PubMed Web of Science ®Google Scholar
• NaimarkD.JacksonE.RockwellE.JesteDV.Psychotic symptoms in Parkinson's disease patients with dementia.J Am Geriatr Soc.1996442962998600200
   PubMed Web of Science ®Google Scholar
• CummingsJL.MillerB.HillMA.NeshkesR.Neuropsychiatrie aspects of multi- infarct dementia and dementia of the Alzheimer type.Arch Neurol.1987443893933827694
   PubMed Web of Science ®Google Scholar
• RayWA.FederspielCF.SchaffnerW.A study of antipsychotic drug use in nursing homes: epidemiologic evidence suggesting misuse.Am J Public Health.1980704854916103676
   PubMed Web of Science ®Google Scholar
• Federal Drug Administration. Omnibus Budget Reconciliation Act Guidelines of 1987. 54 Federal Register. 198953165336
   Google Scholar
• JesteDV.CaligiuriMP.PaulsenJS.et .Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.Arch Gen Psychiatry.1995527567657654127
   PubMed Web of Science ®Google Scholar
• VerhaeverbekeI.MetsT.Drug-induced orthostatic hypotension in the elderly: avoiding its onset.Drug Safety.1997171051189285201
   PubMed Web of Science ®Google Scholar
• HerstL.PowellG.Is clozapine safe in the elderly?Aust N Z J Psychiatry.1997314114179226088
   PubMed Web of Science ®Google Scholar
• HauserWA.Seizure disorders: the changes with age.Epilepsia.199233(suppl4)S6S141425495
   PubMed Web of Science ®Google Scholar
• ChanYC.PariserSF.NeufeldG.Atypical antipsychotics in older adults.Pharmacotherapy19991981182210417029
   PubMed Web of Science ®Google Scholar
• HowanitzE.PardoM.SmelsonDA.et al.The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.J Clin Psychiatry.199960414410074877
   PubMed Web of Science ®Google Scholar
• HoningfeldG.Clozapine versus chlorpromazine in geriatric patients.J Clin Psychiatry.200061636410695651
   PubMed Web of Science ®Google Scholar
• DavidsonM.HarveyPD.VervarckeJ.et al.A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.Int J Geriatr Psychiatry.20001550651410861916
   PubMed Web of Science ®Google Scholar
• MadhusoondananS.BrecherM.BrennerR.et al.Risperidone in the treatment of elderly patients with psychotic disorders.Am J Geriatr Psychiatry.1999713213810322240
   PubMed Web of Science ®Google Scholar
• JesteDV.LacroJP.BaileyA.RockwellE.HarrisMJ.CaligiuriMP.Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.J Am Geriatr Soc.19994771671910366172
   PubMed Web of Science ®Google Scholar
• SajatovicM.PerezD.BrescanD.RamirezLF.Olanzapine therapy in elderly patients with schizophrenia.Psychopharmacol Bull.19983481982310513458
   PubMed Web of Science ®Google Scholar
• StreetJS.ClarkWS.GannonKS.et al.Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group.Arch Gen Psychiatry.20005796897611015815
   PubMed Web of Science ®Google Scholar
• MansonÂJ.SchragA.LeesÂJ.Low-dose olanzapine for levodopainduced dykinesias.Neurology.20005579579910993998
   PubMedGoogle Scholar
• GoetzCG.BlasucciLM.LeurgansS.PappertEJ.Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology.20005578979410993997
   PubMed Web of Science ®Google Scholar
• MolhoES.FactorSA.Worsening of motor features of parkinsonism with olanzapine.Mov Disord.1999141014101610584679
   PubMed Web of Science ®Google Scholar
• RudolfJ.GhaemiM.SchmullingS.Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.Eur Psychiatry.19991435635710572371
   PubMed Web of Science ®Google Scholar
• GrahamJM.SussmanJD.FordKS.SagarHJ.Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.J Neurol Neurosurg Psychiatry.1998657747779810956
   PubMed Web of Science ®Google Scholar
• Jimenez-JimenezFJ.Tallon-BarrancoA.Orti-ParejaM.ZurdoM.PortaJ.MolinaJA.Olanzapine can worsen parkinsonism.Neurology.199850118311849566425
   PubMed Web of Science ®Google Scholar
• DeweyRB.O'SuilleabhainPE.Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease.Neurology.2000551753175411113242
   PubMed Web of Science ®Google Scholar
• FernandezHH.LannonMC.FriedmanJH.AbbottBP.Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.Mov Disord.20001557958110830427
   PubMed Web of Science ®Google Scholar
• WeinerWJ.MinagarA.ShulmanLM.Quetiapine for L-dopa-induced psychosis in PD.Neurology200054153810751276
   PubMed Web of Science ®Google Scholar
• TargumSD.AbbottJL.Efficacy of quetiapine in Parkinson's patients with psychosis.J Clin Psychopharmacol.200020546010653209
   PubMed Web of Science ®Google Scholar
• ParsaMA.BastaniB.Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. )Neuropsychiatry Clin Neurosci.199810216219
   Google Scholar
• MenzaMM.PalermoB.MarkM.Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's d iseases .Ann Clin Psychiatry.19991114114410482124
   PubMedGoogle Scholar
• FernandezHH.FriedmanJH.JacquesC.RosenfeldM.Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.Mov Disord.19991448448710348474
   PubMed Web of Science ®Google Scholar
• McManusDQ.ArvanitisLA.KowalcykBB.Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.J Clin Psychiatry.19996029229810362435
   PubMed Web of Science ®Google Scholar
• TariotPN.SalzmanC.YeungPP.PultzJ.RakIW.Long-term use of quetiapine in elderly patients with psychotic disorders.Clin Ther.2000221068 108411048905
   PubMed Web of Science ®Google Scholar
• MadhusoodananS.BrennerR.AlcantraA.Clinical experience with quetiapine in elderly patients with psychotic disorders.J Geriatr Psychiatry Neurol.200013283210753004
   PubMed Web of Science ®Google Scholar
• KellyDL.ConleyRR.TammingaCA.Differential olanzapine plasma concentrations by sex in a fixed-dose study.Schizophr Res.19994010110410593449
   PubMed Web of Science ®Google Scholar
• MillerDD.FlemingF.HolrnanTL.PerryPJ.Plasma clozapine concentrations as a predictor of clinical response: a follow-up study.J Clin Psychiatry.199455(supplB)1171217961554
   PubMed Web of Science ®Google Scholar
• DixonL.DibietzE.MyersP.ConleyR.MedoffD.LehmanAF.Comparison of DSM-III-R diagnoses and a brief interview for substance abuse among state hospital patients.Hosp Community Psychiatry.1993447487528375835
   PubMedGoogle Scholar
• MueserKT.YarnolclPR.LevinsonDF.et al.Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.Schizophr Bull.19901631562333480
   PubMed Web of Science ®Google Scholar
• AltermanAI.AyreFR.WillifordWO.Diagnostic validation of conjoint schizophrenia and alcoholism.J Clin Psychiatry.1984453003036735989
   PubMed Web of Science ®Google Scholar
• BowersMB.MazureCM.NelsonJC.JatlowPI.Psychotogenic drug use and neuroleptic response.Schizophr Bull.19901681861970670
   PubMed Web of Science ®Google Scholar
• CarpenterMD.MulliganJC.BaderIA.MeinzerAE.Multiple admissions to an urban psychiatric center: a comparative study.Hosp Community Psychiatry.198536130513084086005
   PubMedGoogle Scholar
• GuptaS.HendricksS.KenkelAM.BhatiaSC.HaffkeEA.Relapse in schizophrenia: is there a relationship to substance abuse?Schizophr Res.1996201531568794503
   PubMed Web of Science ®Google Scholar
• HaywoodTW.KravitzHM.GrossmanLS.CavanaughJL.DavisJM.LewisDA.Predicting the “revolving door” phenomenon among patients with schizophrenic, schizoaffective, and affective disorders.Am J Psychiatry.19951528568617755114
   PubMed Web of Science ®Google Scholar
• SullivanG.WellsKB.MorgensternH.LeakeB.Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. AmJ Psychiatry.199515217491756
   Google Scholar
• BaileyLG.MaxwellS.BrandaburMM.Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients.Psychopharmacol Bull.1997331771819133772
   PubMed Web of Science ®Google Scholar
• ConleyRR.KellyDL.GaleEA.Olanzapine response in treatment-refractory schizophrenic patients with a history of substance.Schizophr Res.199833951019783349
   PubMed Web of Science ®Google Scholar
• DrakeRE.OsherFC.WallachMA.Alcohol use and abuse in schizophrenia: a prospective community study.J NervMent Dis.1989177408414
   PubMed Web of Science ®Google Scholar
• SevyS.KaySR.OplerLA.et al.Significance of cocaine history in schizophrenia.J Nerv Ment Dis.19901786426482230749
   PubMed Web of Science ®Google Scholar
• BradyK.AntonR.BallengerJC.et al.Cocaine abuse among schizophrenic patients.Am J Psychiatry.1990147116411672386250
   PubMed Web of Science ®Google Scholar
• CleghornJM.KaplanRD.SzechtmanB.et al.Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive functions.J Clin Psychiatry.19915226301671032
   PubMed Web of Science ®Google Scholar
• BuckleyP.ThompsonP.WayL.MeltzerHY.Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy.Am J Psychiatry.19941513853898109646
   PubMed Web of Science ®Google Scholar
• DixonL.HaasG.WeidenPJ.SweeneyJ.FrancesAJ.Drug abuse in schizophrenic patients: clinical correlates and reasons for use.Am J Psychiatry.19911482242301987823
   PubMed Web of Science ®Google Scholar
• ZisookS.HeatonR.MoranvilleJ.KuckJ.JerniganT.BraffD.Past substance abuse and clinical course of schizophrenia.Am J Psychiatry.19921495525531554046
   PubMed Web of Science ®Google Scholar
• LoveRC.KellyDL.ConleyRR.BartkoJJ.A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics.Schizophr Res.199936345
   Web of Science ®Google Scholar
• RosenheckR.CramerJ.XuW.et al.A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.N Engl J Med.19973378098159295240
   PubMed Web of Science ®Google Scholar
• WeidenP.AquilaR.StandardJ.Atypical antipsychotic drugs and longterm outcome in schizophrenia,J Clin Psychiatry.199657(suppl 11)53608941171
   PubMed Web of Science ®Google Scholar
• GaleE.HirshK.KentD.ConleyR.Clozapine response in treatment resistant schizophrenics with substance abuse.Schizophr Res.199515150151
   Web of Science ®Google Scholar
• AlbaneseMJ.KhantzianEJ.MurphySL.GreenAI.Decreased substance use in chronically psychotic patients treated with clozapine [letter].Am J Psychiatry.19941517807818166327
   PubMed Web of Science ®Google Scholar
• DrakeRE.XieH.McHugoGJ.GreenAI.The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.Schizophr Bull.20002644144910885642
   PubMed Web of Science ®Google Scholar
• ZimmetSV.StrousRD.BurgessES.KohnstammS.GreenAI.Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.J Clin Psychopharmacol.200020949810653215
   PubMed Web of Science ®Google Scholar
• VolavkaJ.The effects of clozapine on aggression and substance abuse in schizophrenic patients.J Clin Psychiatry.199960(suppl 12)434610372611
   PubMed Web of Science ®Google Scholar
• GreenAl.ZimmetSV.StrousRD.SchildkrautJJ.Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?Harv Rev Psychiatry.1999628729610370435
   PubMed Web of Science ®Google Scholar
• FarrenCK.HameediFA.RosenMA.WoodsS.JatlowP.KostenTR.Significant interaction between clozapine and cocaine in cocaine addicts.Drug Alcohol Depend.20005915316310891628
   PubMed Web of Science ®Google Scholar
• JhaA.FourieH.Risperidone treatment of amphetamine psychosis.Br j Psychiatry.199917436610533557
   PubMed Web of Science ®Google Scholar
• MisraLK.KofoedL.FullerW.Treatment of inhalant abuse with risperidone.J Clin Psychiatry.19996062010520984
   PubMed Web of Science ®Google Scholar
• lyoM.SekineY.MatsunagaT.TsukamotoT.TakeiN.MoriN.Methamphetamine- associated obsessional symptoms and effective risperidone treatment: a case report.J Clin Psychiatry.199960337338
   Web of Science ®Google Scholar
• RoyA.RoyM.SmelsonDA.Risperidone, ERG and cocaine craving.Am J Addict.19987909522012
   PubMed Web of Science ®Google Scholar
• SmelsonDA.RoyA.RoyM.Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients.Can J Psychiatry.1997429849429074
   PubMed Web of Science ®Google Scholar
• MisraL.KofoedL.Risperidone treatment of metamphetamine psychosis.Am j Psychiatry.199715411709247413
   PubMed Web of Science ®Google Scholar
• SoykaM.WegnerU.MoellerHJ.Risperidone in treatment-refractory chronic alcohol hallucinosis.Pharmacopsychiatry.1997301351369271781
   PubMed Web of Science ®Google Scholar
• GrabowskiJ.RhoadesH.SilvermanP.et al.Risperidone for the treatment of cocaine dependence: randomized, double-blind trial.J Clin Psychopharmacol.20002030531010831016
   PubMed Web of Science ®Google Scholar
• BerkM.BtookS.TrandafirAI.A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.Int Clin Psychopharmacol.19991417718010435771
   PubMed Web of Science ®Google Scholar
• PenkWE.FlanneryRB.IrvinE.GellerJ.FisherW.HansonMA.Characteristics of substance-abusing persons with schizophrenia: the paradox of the dually diagnosed.J Addict Dis.200019233010772600
   PubMed Web of Science ®Google Scholar
• PrienRF.ColeJO.High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - Psychopharmacology Research Branch Collaborative Study Group.Arch Gen Psychiatry.1968184824954868797
   PubMed Web of Science ®Google Scholar
• DavisJM.CasperR.Antipsychotic drugs: clinical pharmacology and therapeutic use.Drugs.19771426028221069
   PubMed Web of Science ®Google Scholar
• EssockSM.HargreavesWA.DohmFA.GoetheJ.CarverL.HipshmanL.Clozapine eligibility among state hospital patients.Schizophr Bull.19962215258685657
   PubMed Web of Science ®Google Scholar
• McGlashanTH.A selective review of recent North American long-term follow-up studies of schizophrenia.Schizophr Bull.1988145155423064280
   PubMed Web of Science ®Google Scholar
• KaneJ.HonigfeldG.SingerJ.MeltzerH.Clozapine for the treatmentresistant schizophrenic.Arch Gen Psychiatry.1988457897963046553
   PubMed Web of Science ®Google Scholar
• HoldenJM.ItilTM.KeskinerA.FinkM.Thiordazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia.Compr Psychiatry.196896336434883430
   PubMed Web of Science ®Google Scholar
• SmallJG.KellamsJJ.MilsteinV.MooreJ.A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients.Am J Psychiatry.1975132131513171106217
   PubMed Web of Science ®Google Scholar
• LingjaerdeO.EngstrandE.EllingsenP.StyloDA.RobakOH.Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial.CurrTherRes.197926505512
   Google Scholar
• RuskinP.AverbukhI.BelmakerRH.DasbergH.Benzodiazepines in chronic schizophrenia.Biol Psychiatry.197914557558476236
   PubMed Web of Science ®Google Scholar
• CarmanJS.BigelowLB.WyattRJ.Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients.J Clin Psychiatry.1981421241286110654
   PubMed Web of Science ®Google Scholar
• WolkowitzOM.PickarD.DoranAR.BreierA.TarellJ.PaulSM.Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.Am J Psychiatry.198614385872867690
   PubMed Web of Science ®Google Scholar
• BrennerHD.DenckerSJ.GoldsteinMJ.et al.Defining treatment refractoriness in schizophrenia.Schizophr Bull.1990165515611981813
   PubMed Web of Science ®Google Scholar
• ChristisonGW.KirchDG.WyattRJ.When symptoms persist: choosing among alternative somatic treatments for schizophrenia.Schizophr Bull.1991172172451679252
   PubMed Web of Science ®Google Scholar
• MeltzerHY.Defining treatment refractoriness in schizophrenia.SchizophrBull.199016563565
   PubMed Web of Science ®Google Scholar
• KinonBJ.KaneJM.JohnsC.et al.Treatment of neuroleptic-resistant schizophrenia relapse.Psychopharmacol Bull.1993293093147904762
   PubMedGoogle Scholar
• ShalevA.HermeshH.RothbergJ.MunitzH.Poor neuroleptic response in acutely exacerbated schizophrenic patients.Acta Psychiatr Scand.19938786918095362
   PubMed Web of Science ®Google Scholar
• BarnesTR.McEvedyCJ.Pharmacological treatment strategies in the non-responsive schizophrenic patient.Int Clin Psychopharmacol.199611(suppl2)67718803663
   PubMed Web of Science ®Google Scholar
• Physicians Desk Reference. Montvale, NY: Medical Economics Company;2000
   Google Scholar
• KaneJM.MarderSR.Psychopharmacologic treatment of schizophrenia.Schizophr Bull.1993192873028100642
   PubMed Web of Science ®Google Scholar
• FardeL.NordstromAL.WieselFA.PauliS.HalldinC.SedvallG.Positron emission tomographic analysis of central D, and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.Arch Gen Psychiatry.1992495385441352677
   PubMed Web of Science ®Google Scholar
• RifkinA.QuitkinF.RabinerCJ.KleinDF.Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: I. Relapse rates after 1 year.Arch Gen Psychiatry.1977344347189724
   PubMed Web of Science ®Google Scholar
• BaldessariniRJ.CohenBM.TeicherM.Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.Arch Gen Psychiatry.19884579912892478
   PubMed Web of Science ®Google Scholar
• Van PuttenT.MarderSR.MintzJ.A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.Arch Gen Psychiatry.1990477547582378546
   PubMed Web of Science ®Google Scholar
• DixonLB.LehmanAF.LevineJ.Conventional antipsychotic medications for schizophrenia.Schizophr Bull.1995215675778749885
   PubMed Web of Science ®Google Scholar
• DenckerSJ.KulhanetF.edsTreatment Resistance in Schizophrenia. Braunschweig, Germany: Vieweg Verlag;1988
   Google Scholar
• SternRG.KahnRS.DavidsonM.Predictors of response to neuroleptic treatment in schizophrenia.Psychiatr Clin North Am.1993163133388101371
   PubMed Web of Science ®Google Scholar
• BilderRM.WuH.ChakosMH.et al.Cerebral morphometry and clozapine treatment in schizophrenia,j Clin Psychiatry.199455(suppl B)53567961574
   PubMed Web of Science ®Google Scholar
• OtaP.MaeshiroH.IshidoH.et al.Treatment resistant chronic psychopathology and CT scans in schizophrenia.Acta Psychiatr Scand.1987754154273591423
   PubMed Web of Science ®Google Scholar
• Van KammenDP.SchoolerN.Are biochemical markers for treatmentresistant schizophrenia state dependent or traits?Clin Neuropharmacol.199013(suppl 1)S16S282199034
   PubMed Web of Science ®Google Scholar
• PickarD.BreierA.KelsoeJ.Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.Ann N Y AcadSci.1988537339346
   PubMed Web of Science ®Google Scholar
• RodriguezVM.CatalinaML.Garcia-NoblejasJA.CuestaP.Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia.Psychiatry Res.199877212810710171
   PubMed Web of Science ®Google Scholar
• BreierA.BuchananRW.KirkpatrickB.et al.Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.Am J Psychiatry.199415120268267129
   PubMed Web of Science ®Google Scholar
• ConleyRR.BuchananRW.Evaluation of treatment-resistant schizophrenia.Schizophr Bull.1997236636749366002
   PubMed Web of Science ®Google Scholar
• BakTH.BauerM.SchaubRT.HellwegR.ReischiesFM.Myoclonus in patients treated with clozapine: a case series,J Clin Psychiatry.1995564184227665541
   PubMed Web of Science ®Google Scholar
• WirshingDA.MarshallBD.GreenMF.MintzJ.MarderSR.WirshingWC.Risperidone in treatment-refractory schizophrenia.Am j Psychiatry.19991561374137910484947
   PubMed Web of Science ®Google Scholar
• WahlbeckK.CheineM.TuiskuK.AhokasA.JoffeG.RimonR.Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.Prog Neuropsychopharmacol Biol Psychiatry.20002491192211041534
   PubMed Web of Science ®Google Scholar
• BondolfiG.DufourH.PatrisM.etal.Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.Am J Psychiatry.19981 554995049545995
   PubMedGoogle Scholar
• FlynnSW.MacEwanGW.AltmanS.et al.An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.Pharmacopsychiatry.19983125299524981
   PubMed Web of Science ®Google Scholar
• BreierA.HamiltonSH.Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biol Psychiatry.19994540341110071708
   PubMed Web of Science ®Google Scholar
• MartinJ.GomezJC.Garcia-BernardoE.CuestaM.AlvarezE.GurpeguiM.Olanzapine in treatment-refractory schizophrenia: results of an openlabel study. The Spanish Group for the Study of Olanzapine in TreatmentRefractory Schizophrenia.J Clin Psychiatry.1997584794839413413
   PubMed Web of Science ®Google Scholar
• DossenbachMRK.BeuzenJN.AvnonM.et al.The effectivness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapineClin Ther2000221021103411048902
   PubMed Web of Science ®Google Scholar
• ConleyRR.TammingaCA.BartkoJJ.et al.Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.Am J Psychiatry.19981559149209659857
   PubMed Web of Science ®Google Scholar
• ConleyRR.TammingaCA.KellyDL.RichardsonCM.Treatment-resistant schizophrenic patients respond to clozapine after olanzapine nonresponse.Biol Psychiatry.199946737710394475
   PubMed Web of Science ®Google Scholar
• SandersRD.MossmanD.An open trial of olanzapine in patients with treatment-refractory psychoses.J Clin Psychopharmacol.19991962669934945
   PubMed Web of Science ®Google Scholar
• ReznikI.BenatovR.SirotaP.Seroquel in a resistant schizophrenic with negative and positive symptoms [in Hebrew].Harefuah.1996130675677,7278794656
   PubMedGoogle Scholar
• FabreLF.ArvanitisL.PultzJ.JonesVM.MalickJB.SlotnickVB.ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.Clin Ther.1995173663787585841
   PubMed Web of Science ®Google Scholar
• EmsleyRA.RaniwallaJ.BaileyPJ.JonesAM.A comparison of the effects of quetiapine (“seroquel”) and haloperidol in schizophrenic patients with a history of a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group.Int Clin Psychopharmacol.20001512113110870870
   PubMed Web of Science ®Google Scholar
• GroweGA.CraytonJW.KlassDB.EvansH.StrizichM.Lithium in chronic schizophrenia.Am j Psychiatry.1979136(4A)45445534327
   PubMed Web of Science ®Google Scholar
• JohnsCA.ThompsonJW.Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy.Schizophr Bull.1995216076198749888
   PubMed Web of Science ®Google Scholar
• SchulzSC.ThompsonPA.JacobsM.et al.Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.J Clin Psychiatry.19996036637210401914
   PubMed Web of Science ®Google Scholar
• MartinJC.PalencianoG.PerezR.The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia.J Clin Psychiatry.20006194811206602
   PubMed Web of Science ®Google Scholar
• CohenWJ.CohenNH.Lithium carbonate, haloperidol and irreversible brain damage.JAMA.1974230128312874479505
   PubMed Web of Science ®Google Scholar
• MillerF.MenningerJ.Lithium-neuroleptic neurotoxicity is dose-dependent.J Psychopharmacol.198778991
   Web of Science ®Google Scholar
• PostRM.Non-lithium treatment for bipolar disorder.J Clin Psychiatry.199051(suppl)9162116406
   PubMed Web of Science ®Google Scholar
• FreemanTW.ClothierJL.PazzagliaP.LesemMD.SwannAC.A doubleblind comparison of valproate and lithium in the treatment of acute mania.Am J Psychiatry.19921491081111728157
   PubMed Web of Science ®Google Scholar
• KahnEM.SchulzSC.PerelJM.AlexanderJE.Change in haloperidol level due to carbamazepine - a complicating factor in combined medication for schizophrenia,J Clin Psychiatry.1990105457
   Google Scholar
• DursunSM.McintoshD.MillikenH.Clozapine plus lamotrigine in treatment-resistant schizophrenia.Arch Gen Psychiatry.19995695010530638
   PubMed Web of Science ®Google Scholar
• TharyanP.Electroconvulsive therapy for schizophrenia.Cochrane Database Syst Rev.2000CD000076
   Google Scholar
• KupchikM.SpivakB.MesterR.et al.Combined electoconvulsive clozapine therapy.Clin Neuropharmacol.200023141610682225
   PubMed Web of Science ®Google Scholar
• KalesHC.DequardoJR.TandonR.Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry.19992354795610378236
   PubMed Web of Science ®Google Scholar
• BhatiaSC.BhatiaSK.GuptaS.Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatmentresistant schizophrenia.J ECT.1998142802839871852
   PubMed Web of Science ®Google Scholar
• BenatovR.SirotaP.MeggedS.Neuroleptic-resistant schizophrenia treated with clozapine and ETC.Convulsive Ther.199612117121
   PubMedGoogle Scholar
• RemingtonGJ.AddingtonD.CollinsEJ.et al.Clozapine: current status and role in the pharmacotherapy of schizophrenia.Can J Psychiatry.1996411611668722645
   PubMedGoogle Scholar
• KeksNA.AltsonK.HopeJ.et al.Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service.AustNZJ Psychiatry.199933896901
   PubMed Web of Science ®Google Scholar
• StahlSM.Antipsychotic polypharmacy. Part 1. Therapeutic option or dirty little secret?J Clin Psychiatry.19996042542610453794
   PubMed Web of Science ®Google Scholar
• AdesanyaA.PantelisC.Adjunctive risperidone treatment in patients with “clozapine-resistant schizophrenia.”Aust NZJ Psychiatry.200034533534
   PubMed Web of Science ®Google Scholar
• HendersonDC.GoffDC.Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.J Clin Psychiatry.1996573953979746446
   PubMed Web of Science ®Google Scholar
• RaskinS.KatzG.ZislinZ.KnoblerHY.DurstR.Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.Acta Psychiatr Scand.200010133433610782556
   PubMed Web of Science ®Google Scholar
• MoreraAL.BarreiroP.Cano-MunozJL.Risperidone and clozapine combination for the treatment of refractory schizophrenia.Acta Psychiatr Scand.19999930530610223435
   PubMed Web of Science ®Google Scholar
• McCarthyRH.TerkelsenKG.Risperidone augmentation of clozapine.Pharmacopsychiatry.19952861637542786
   PubMed Web of Science ®Google Scholar
• GuptaS.SonnenbergSJ.FrankB.Olanzapine augmentation of clozapine.Ann Clin Psychiatry.1998101131159781474
   PubMedGoogle Scholar
• LemerV.ChudakovaB.KravetsS.PolyakovaI.Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.Clin Neuropharmacol.20002328428611154098
   PubMed Web of Science ®Google Scholar
• MowermanS.SirisSG.Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients.Ann Clin Psychiatry.199681931978986313
   PubMedGoogle Scholar
• RankinS.DustR.KatzG.ZislanJ.Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia,J Clin Psychopharmacol.20002050050311001233
   PubMed Web of Science ®Google Scholar
• ShilohR.ZemishlanyZ.AizenbergD.et al.Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A doubleblind, placebo-controlled study.Br J Psychiatry.19971715695739519099
   PubMed Web of Science ®Google Scholar
• FriedmanJ.AultK.PowchikP.Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.Biol Psychiatry.1997425225239285089
   PubMed Web of Science ®Google Scholar
• WolkowitzOM.TuretskyN.ReusVI.HargreavesWA.Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia.Psychopharmacol Bull.1992282912951362277
   PubMedGoogle Scholar
• HanlonTE.OtaKY.KurlandAA.Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine.Disord Nerv System.197031171177
   PubMedGoogle Scholar
• PatoC., Wolkowitz OM, Rapaport M, Schulz SC, Pickar D. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia.Psychopharmacol Bull.1989252632662574897
   PubMedGoogle Scholar
• WahlbeckK.CheineMV.GilbodyS.AhonenJ.Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials.Schizophr Res.20004134134710708343
   PubMed Web of Science ®Google Scholar